Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: A time for reassessment?

Paul A. Bunn, James Mault, Karen Kelly

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Surgical resection has limited success in curing non-small cell lung cancer (NSCLC), particularly among patients with locally advanced disease (stage IIIA). Combined modality regimens, utilizing surgery, radiotherapy, and chemotherapy, have improved response rates, although they have not been shown to significantly impact survival among patients with completely resetted stage I and II NSCLC. Future improvements in NSCLC therapy, currently under investigation, are likely to come from newer agents shown to be active in this disease and from alternative schedules, such as neoadjuvant or concurrent combined modality treatments. Neoadjuvant cisplatin-based chemotherapy has already been shown to increase cure rates in stage IIIA NSCLC, from 10 to 15% to 25 to 30%. Newer active agents, such as paclitaxel, vinorelbine, and gemcitabine, may be able to advance the cure rate even further. Radiotherapy, which has been shown to decrease the rate of local recurrence, may play a role as well.

Original languageEnglish (US)
Issue number4 SUPPL. 1
StatePublished - 2000
Externally publishedYes


  • Adjuvant therapy
  • Cisplatin
  • Lymph nodes
  • Neoadjuvant therapy
  • Non-small cell lung cancer
  • Radiotherapy
  • Recurrence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: A time for reassessment?'. Together they form a unique fingerprint.

Cite this